Cocrystal Pharma Inc (COCP)
1.88
+0.15
(+8.67%)
USD |
NASDAQ |
Nov 04, 16:00
1.88
0.00 (0.00%)
After-Hours: 20:00
Cocrystal Pharma Research and Development Expense (TTM): 15.72M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 15.72M |
| March 31, 2024 | 14.21M |
| December 31, 2023 | 15.17M |
| September 30, 2023 | 14.19M |
| June 30, 2023 | 13.87M |
| March 31, 2023 | 13.43M |
| December 31, 2022 | 12.39M |
| September 30, 2022 | 11.84M |
| June 30, 2022 | 10.07M |
| March 31, 2022 | 10.27M |
| December 31, 2021 | 8.972M |
| September 30, 2021 | 6.937M |
| June 30, 2021 | 6.909M |
| March 31, 2021 | 6.328M |
| December 31, 2020 | 6.034M |
| September 30, 2020 | 6.294M |
| June 30, 2020 | 5.294M |
| March 31, 2020 | 4.409M |
| December 31, 2019 | 4.004M |
| September 30, 2019 | 4.249M |
| June 30, 2019 | 4.639M |
| March 31, 2019 | 4.667M |
| December 31, 2018 | 4.666M |
| September 30, 2018 | 4.567M |
| June 30, 2018 | 4.493M |
| Date | Value |
|---|---|
| March 31, 2018 | 4.629M |
| December 31, 2017 | 5.823M |
| September 30, 2017 | 98.60M |
| June 30, 2017 | 99.30M |
| March 31, 2017 | 100.41M |
| December 31, 2016 | 101.68M |
| September 30, 2016 | 49.31M |
| June 30, 2016 | 49.40M |
| March 31, 2016 | 48.98M |
| December 31, 2015 | 47.19M |
| September 30, 2015 | 7.032M |
| June 30, 2015 | 5.721M |
| March 31, 2015 | 4.663M |
| December 31, 2014 | 4.07M |
| September 30, 2014 | 3.647M |
| June 30, 2014 | 3.731M |
| March 31, 2014 | 3.823M |
| December 31, 2013 | 3.861M |
| September 30, 2013 | 2.840M |
| June 30, 2013 | 2.046M |
| March 31, 2013 | 1.273M |
| December 31, 2012 | 0.4893M |
| September 30, 2012 | 0.8881M |
| June 30, 2012 | 0.7361M |
| March 31, 2012 | 0.583M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
4.004M
Minimum
Dec 2019
15.72M
Maximum
Jun 2024
9.807M
Average
10.07M
Median
Jun 2022
Research and Development Expense (TTM) Benchmarks
| Perspective Therapeutics Inc | 28.53M |
| Alaunos Therapeutics Inc | 4.895M |
| Oragenics Inc | 13.38M |
| Cara Therapeutics Inc | 85.14M |
| Jaguar Health Inc | 17.51M |